We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper ...

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

A breakthrough in our understanding of mRNA delivery systems in the body may allow for more direct treatments for ...

Heart attacks remain a leading cause of death and disability worldwide. The permanent loss of heart muscle cells—known as ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

A team from the Max-Planck-Institut für Kohlenforschung, Hokkaido University, and Osaka University has discovered that subtle differences in molecular structure can have a major impact on the ...

Stock futures edged down Friday morning as investor sentiment took a hit from concerns over the economic impact of higher ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

What if mRNA vaccines could be made more powerful and less irritating? Scientists at the University of Pennsylvania have ...